DASP

Dannex Ayrton StarwinGHSE:DASPHARMA Stock Report

Market Cap

GH₵0

7D

0%

1Y

n/a

Updated

17 Oct, 2021

Data

Company Financials
DASPHARMA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

DASPHARMA Overview

Dannex Ayrton Starwin Plc manufactures and sells pharmaceutical products in Ghana.

Price History & Performance

Summary of all time highs, changes and price drops for Dannex Ayrton Starwin
Historical stock prices
Current Share PriceGH₵0.40
52 Week HighGH₵0
52 Week LowGH₵0
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO0%

Recent News & Updates

Shareholder Returns

DASPHARMAGH PharmaceuticalsGH Market
7D0%2.4%-0.8%
1Yn/a87.5%67.3%

Return vs Industry: Insufficient data to determine how DASPHARMA performed against the GH Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how DASPHARMA performed against the GH Market.

Price Volatility

Is DASPHARMA's price volatile compared to industry and market?
DASPHARMA volatility
DASPHARMA Beta0
Industry Beta0.56
Market Beta1

Stable Share Price: Insufficient data to determine DASPHARMA's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine DASPHARMA's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aDaniel Kwabena Kissihttps://dasgh.com

Dannex Ayrton Starwin Plc manufactures and sells pharmaceutical products in Ghana. The company offers a range of products in various categories, such as analgesics, hematinics, anti-tussives, dermatological products, anti-convulsing, and anti-asthmatics in form of tablets, capsules, liquids, powders, ointments, and chemicals. It provides its products under the Durol, Virol, Samalin, Teeder, Koffex, ORS, Rapinol, Asmadrin, and Milk of Magnesia names.

Dannex Ayrton Starwin Fundamentals Summary

How do Dannex Ayrton Starwin's earnings and revenue compare to its market cap?
DASPHARMA fundamental statistics
Market Capn/a
Earnings (TTM)GH₵0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DASPHARMA income statement (TTM)
RevenueGH₵0
Cost of RevenueGH₵0
Gross ProfitGH₵0
ExpensesGH₵0
EarningsGH₵0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did DASPHARMA perform over the long term?

See historical performance and comparison

Valuation

Is Dannex Ayrton Starwin undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Dannex Ayrton Starwin is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Dannex Ayrton Starwin has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Dannex Ayrton Starwin forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dannex Ayrton Starwin has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Dannex Ayrton Starwin performed over the past 5 years?

12.8%

Historical Pharmaceuticals & Biotech annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Dannex Ayrton Starwin has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Financial Health

How is Dannex Ayrton Starwin's financial position?


In this section we usually analyse Dannex Ayrton Starwin's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Dannex Ayrton Starwin has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Dividend

What is Dannex Ayrton Starwin current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DASPHARMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DASPHARMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DASPHARMA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DASPHARMA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DASPHARMA's dividend in 3 years as they are not forecast to pay a notable one for the GH market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Daniel Kwabena Kissi (54 yo)

no data

Tenure

Mr. Daniel Kwabena Apeagyei Kissi has been Managing Director of Ayrton Drugs Manufacturing Company Ltd. since December 01, 2012 and also it's Chief Executive Officer. He has been Chief Executive Officer an...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Dannex Ayrton Starwin Plc's employee growth, exchange listings and data sources


Key Information

  • Name: Dannex Ayrton Starwin Plc
  • Ticker: DASPHARMA
  • Exchange: GHSE
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: GH₵0
  • Shares outstanding: 0
  • Website: https://dasgh.com

Location

  • Dannex Ayrton Starwin Plc
  • No. 5 Dadeban Road
  • Ring Road North
  • Accra
  • Ghana

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/17 17:03
End of Day Share Price2021/09/20 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.